On 15 January 2015, orphan designation (EU/3/14/1426) was granted by the European Commission to Richardson Associates Regulatory Affairs Ltd, United Kingdom, for allogeneic peripheral blood mononuclear cells induced to an early apoptotic state for the prevention of graft-versus-host disease.
The sponsorship was transferred to Richardson Associates Regulatory Affairs Ltd, Ireland, in December 2018.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.
Allogeneic peripheral blood mononuclear cells induced to an early apoptotic state
Prevention of graft-versus-host disease
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
EU/3/14/1426: Public summary of opinion on orphan designation: Allogeneic peripheral blood mononuclear cells induced to an early apoptotic state for the prevention of graft-versus-host disease (PDF/236.61 KB)
First published: 06/03/2015
Last updated: 28/02/2022
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: